I期临床-话题@MedSci

#I期临床#

570篇内容 | 7002人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1653242, encodeId=2d9b1653242b8, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=博生吉PA3-17注射液I期临床首例受试者回输, objectType=article, longId=724802, objectId=2be9e24802d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2be9e24802d4, replyNumber=0, likeNumber=98, createdTime=2023-03-29, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2be9e24802d4, moduleTitle=博生吉PA3-17注射液I期临床首例受试者回输, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2be9e24802d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653217, encodeId=6e91165321ebe, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=“吹口气测新冠”成为可能，mRNA疫苗加强针III期临床试验保护效力为95.6%丨新冠研究一周进展, objectType=article, longId=219261, objectId=3c982192618a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c982192618a, replyNumber=0, likeNumber=73, createdTime=2022-01-15, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c982192618a, moduleTitle=“吹口气测新冠”成为可能，mRNA疫苗加强针III期临床试验保护效力为95.6%丨新冠研究一周进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c982192618a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653244, encodeId=4e26165324471, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=辉瑞新冠口服药Paxlovid用于暴露后预防的II/III期临床失败, objectType=article, longId=725951, objectId=a6bfe25951ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6bfe25951ed, replyNumber=0, likeNumber=79, createdTime=2022-12-09, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6bfe25951ed, moduleTitle=辉瑞新冠口服药Paxlovid用于暴露后预防的II/III期临床失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a6bfe25951ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653223, encodeId=2d7516532231f, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Front Oncol：Lenvatinib（仑伐替尼）联合PD-1抑制剂一线治疗初始不可切除胆道癌(BTC)的疗效和安全性：单臂、开放标签II期临床研究, objectType=article, longId=221179, objectId=74cf2211e969, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74cf2211e969, replyNumber=0, likeNumber=98, createdTime=2021-12-23, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74cf2211e969, moduleTitle=Front Oncol：Lenvatinib（仑伐替尼）联合PD-1抑制剂一线治疗初始不可切除胆道癌(BTC)的疗效和安全性：单臂、开放标签II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74cf2211e969)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653232, encodeId=6df316532322d, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Ann Oncol：II期临床研究ROAR更新：Dabrafenib(达拉菲尼)联合trametinib(曲美替尼)治疗BRAF V600E突变间变性甲状腺癌的疗效, objectType=article, longId=295362, objectId=66af295362ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66af295362ac, replyNumber=0, likeNumber=80, createdTime=2022-11-14, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66af295362ac, moduleTitle=Ann Oncol：II期临床研究ROAR更新：Dabrafenib(达拉菲尼)联合trametinib(曲美替尼)治疗BRAF V600E突变间变性甲状腺癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66af295362ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653226, encodeId=d12d16532263c, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=NEJM：新冠抗体鸡尾酒疗法REGEN-COV III期临床研究结果喜人, objectType=article, longId=221687, objectId=bc7922168e72, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc7922168e72, replyNumber=0, likeNumber=79, createdTime=2022-07-11, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc7922168e72, moduleTitle=NEJM：新冠抗体鸡尾酒疗法REGEN-COV III期临床研究结果喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc7922168e72)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653197, encodeId=8803165319e87, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Lancet Infect Dis：陈薇团队研发的雾化吸入用新冠疫苗I期临床试验结果发布, objectType=article, longId=215013, objectId=499f215013f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=499f215013f2, replyNumber=0, likeNumber=110, createdTime=2022-04-27, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=499f215013f2, moduleTitle=Lancet Infect Dis：陈薇团队研发的雾化吸入用新冠疫苗I期临床试验结果发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=499f215013f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653247, encodeId=7f80165324ec8, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=JCO：口服SERD艾拉司群治疗ER+/HER2-晚期乳腺癌安全有效！EMERALD III期临床最新数据出炉！, objectType=article, longId=727998, objectId=c0e7e2799863, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0e7e2799863, replyNumber=0, likeNumber=116, createdTime=2023-02-12, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0e7e2799863, moduleTitle=JCO：口服SERD艾拉司群治疗ER+/HER2-晚期乳腺癌安全有效！EMERALD III期临床最新数据出炉！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0e7e2799863)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653234, encodeId=04bf165323487, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=君实生物特瑞普利单抗联合化疗作为术后辅助治疗胃癌III期临床研究完成首例患者给药, objectType=article, longId=295432, objectId=53a8295432d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=53a8295432d2, replyNumber=0, likeNumber=84, createdTime=2022-09-20, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=53a8295432d2, moduleTitle=君实生物特瑞普利单抗联合化疗作为术后辅助治疗胃癌III期临床研究完成首例患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=53a8295432d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653230, encodeId=020b16532307c, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=知临集团宣布完成针对金黄色葡萄球菌和神经母细胞瘤感染的小分子药物ALS-4和SACT-1的I期临床试验, objectType=article, longId=293895, objectId=2b072938950e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b072938950e, replyNumber=0, likeNumber=74, createdTime=2022-06-07, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b072938950e, moduleTitle=知临集团宣布完成针对金黄色葡萄球菌和神经母细胞瘤感染的小分子药物ALS-4和SACT-1的I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b072938950e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653202, encodeId=72d316532023c, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Liver Cnacer：mTOR抑制剂Temsirolimus联合索拉非尼治疗晚期肝细胞癌的疗效和安全性：II期临床研究, objectType=article, longId=216786, objectId=af4a216e8623, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af4a216e8623, replyNumber=0, likeNumber=82, createdTime=2021-10-28, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af4a216e8623, moduleTitle=Liver Cnacer：mTOR抑制剂Temsirolimus联合索拉非尼治疗晚期肝细胞癌的疗效和安全性：II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af4a216e8623)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653221, encodeId=d4c01653221b5, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=安可达III期临床研究设计及数据解读, objectType=article, longId=220755, objectId=9535220e55a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9535220e55a8, replyNumber=0, likeNumber=48, createdTime=2022-01-03, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9535220e55a8, moduleTitle=安可达III期临床研究设计及数据解读, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9535220e55a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653243, encodeId=2b9c16532435f, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=PA3-17注射液治疗成人复发/难治性CD7阳性血液淋巴系统恶性肿瘤患者的I期临床研究, objectType=article, longId=724803, objectId=de5ee24803e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de5ee24803e5, replyNumber=0, likeNumber=106, createdTime=2022-06-05, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de5ee24803e5, moduleTitle=PA3-17注射液治疗成人复发/难治性CD7阳性血液淋巴系统恶性肿瘤患者的I期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=de5ee24803e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653200, encodeId=997316532004d, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Noxopharm的TBK1抑制剂idronoxil I期临床试验显示新冠肺炎患者有抗炎应答, objectType=article, longId=216356, objectId=c32b21635692, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c32b21635692, replyNumber=0, likeNumber=89, createdTime=2022-01-13, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c32b21635692, moduleTitle=Noxopharm的TBK1抑制剂idronoxil I期临床试验显示新冠肺炎患者有抗炎应答, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c32b21635692)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653191, encodeId=55c1165319173, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=JCO: Ixazomi联合来那度胺+地塞米松治疗复发或难治性多发性骨髓瘤（RRMM）的最终分析结果：III期临床研究TOURMALINE-MM1, objectType=article, longId=212671, objectId=87bb2126e1d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87bb2126e1d5, replyNumber=0, likeNumber=84, createdTime=2022-01-31, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87bb2126e1d5, moduleTitle=JCO: Ixazomi联合来那度胺+地塞米松治疗复发或难治性多发性骨髓瘤（RRMM）的最终分析结果：III期临床研究TOURMALINE-MM1, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=87bb2126e1d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653187, encodeId=40ef165318ed6, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=百时美施贵宝公布III期临床研究CheckMate -9LA两年随访数据，结果喜人！, objectType=article, longId=210359, objectId=837e210359f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=837e210359f2, replyNumber=0, likeNumber=72, createdTime=2021-11-17, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=837e210359f2, moduleTitle=百时美施贵宝公布III期临床研究CheckMate -9LA两年随访数据，结果喜人！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=837e210359f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653177, encodeId=0b0116531e7d7, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=2021年4月19日全球新冠肺炎（COVID-19）疫情简报，确诊超1亿4198万，国内保护力更强的灭活疫苗和mRNA疫苗均即将进入III期临床试验, objectType=article, longId=210178, objectId=c5462101e853, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5462101e853, replyNumber=0, likeNumber=74, createdTime=2021-08-05, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5462101e853, moduleTitle=2021年4月19日全球新冠肺炎（COVID-19）疫情简报，确诊超1亿4198万，国内保护力更强的灭活疫苗和mRNA疫苗均即将进入III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5462101e853)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653227, encodeId=9d83165322ee8, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=NEJM：Tapinarof乳膏局部治疗银屑病III期临床获得成功, objectType=article, longId=221809, objectId=99492218096b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99492218096b, replyNumber=0, likeNumber=86, createdTime=2022-09-08, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99492218096b, moduleTitle=NEJM：Tapinarof乳膏局部治疗银屑病III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=99492218096b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653203, encodeId=0f9916532032a, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Lung Cancer：多西他赛vs多西他赛+厄洛替尼治疗复发晚期非鳞状非小细胞肺癌的疗效：III期临床研究NVALT-18, objectType=article, longId=216915, objectId=e8b0216915a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8b0216915a0, replyNumber=0, likeNumber=85, createdTime=2022-07-27, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8b0216915a0, moduleTitle=Lung Cancer：多西他赛vs多西他赛+厄洛替尼治疗复发晚期非鳞状非小细胞肺癌的疗效：III期临床研究NVALT-18, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8b0216915a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653211, encodeId=24df1653211cb, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Proxalutamide用于治疗美国住院COVID-19患者的III期临床试验，首次对患者给药, objectType=article, longId=218128, objectId=301e21812880, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=301e21812880, replyNumber=0, likeNumber=76, createdTime=2022-09-02, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=301e21812880, moduleTitle=Proxalutamide用于治疗美国住院COVID-19患者的III期临床试验，首次对患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=301e21812880)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

I期临床

2020-05-29

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

博生吉PA3-17注射液I期临床首例受试者回输

2023-03-29

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

“吹口气测新冠”成为可能，mRNA疫苗加强针III期临床试验保护效力为95.6%丨新冠研究一周进展

2022-01-15

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

辉瑞新冠口服药Paxlovid用于暴露后预防的II/III期临床失败

2022-12-09

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Front Oncol：Lenvatinib（仑伐替尼）联合PD-1抑制剂一线治疗初始不可切除胆道癌(BTC)的疗效和安全性：单臂、开放标签II期临床研究

2021-12-23

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Ann Oncol：II期临床研究ROAR更新：Dabrafenib(达拉菲尼)联合trametinib(曲美替尼)治疗BRAF V600E突变间变性甲状腺癌的疗效

2022-11-14

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

NEJM：新冠抗体鸡尾酒疗法REGEN-COV III期临床研究结果喜人

2022-07-11

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Lancet Infect Dis：陈薇团队研发的雾化吸入用新冠疫苗I期临床试验结果发布

2022-04-27

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

JCO：口服SERD艾拉司群治疗ER+/HER2-晚期乳腺癌安全有效！EMERALD III期临床最新数据出炉！

2023-02-12

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

君实生物特瑞普利单抗联合化疗作为术后辅助治疗胃癌III期临床研究完成首例患者给药

2022-09-20

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

知临集团宣布完成针对金黄色葡萄球菌和神经母细胞瘤感染的小分子药物ALS-4和SACT-1的I期临床试验

2022-06-07

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Liver Cnacer：mTOR抑制剂Temsirolimus联合索拉非尼治疗晚期肝细胞癌的疗效和安全性：II期临床研究

2021-10-28

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

安可达III期临床研究设计及数据解读

2022-01-03

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

PA3-17注射液治疗成人复发/难治性CD7阳性血液淋巴系统恶性肿瘤患者的I期临床研究

2022-06-05

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Noxopharm的TBK1抑制剂idronoxil I期临床试验显示新冠肺炎患者有抗炎应答

2022-01-13

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

JCO: Ixazomi联合来那度胺+地塞米松治疗复发或难治性多发性骨髓瘤（RRMM）的最终分析结果：III期临床研究TOURMALINE-MM1

2022-01-31

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

百时美施贵宝公布III期临床研究CheckMate -9LA两年随访数据，结果喜人！

2021-11-17

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

2021年4月19日全球新冠肺炎（COVID-19）疫情简报，确诊超1亿4198万，国内保护力更强的灭活疫苗和mRNA疫苗均即将进入III期临床试验

2021-08-05

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

NEJM：Tapinarof乳膏局部治疗银屑病III期临床获得成功

2022-09-08

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Lung Cancer：多西他赛vs多西他赛+厄洛替尼治疗复发晚期非鳞状非小细胞肺癌的疗效：III期临床研究NVALT-18

2022-07-27

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Proxalutamide用于治疗美国住院COVID-19患者的III期临床试验，首次对患者给药

2022-09-02

科室
- - 订阅+
  - 更多科室
工具
服务